PURPOSE: Oral mucositis (OM) is a side effect of intensive chemotherapy and radiation and has been reported to affect 75-100% of hematopoietic stem cell transplantation (HSCT) recipients. The purpose of this study was to compare the incidence of OM in patients conditioned with myeloablative conditioning (MAC) to reduced-intensity conditioning (RIC) and to determine the effect of a new oral care protocol. METHODS: The study involved 171 HSCT recipients, with hematological malignancies transplanted between 2007 and 2011. Median age of the patients was 50 years (range 12-71). Ninety-nine (58%) received RIC and 72 received MAC. Clinical features of OM were recorded from day -3 before to day +25 after HSCT using the World Health Organization (WHO) scoring system and the oral mucositis assessment score (OMAS). RESULTS: Overall, 87% of the patients developed OM of any severity, which peaked on days 10-11. The mean WHO score was 1.7. In multivariate analysis, the severity of OM was associated with MAC (relative hazard (RH) 1.57, 95% confidence interval (CI) 1.37-1.80, p < 0.001), all donor-recipient gender combinations except female-to-male (RH = 1.26, 95% CI 1.10-1.4, p = 0.001), and early year of HSCT (RH = 0.84, 95%CI 0.7-0.96, p = 0.013). There was a correlation between long hospitalization and OM (day 15, r = 0.31, p < 0.001). There was a good correlation between the WHO and OMAS scoring systems for OM (r = 0.74, p < 0.001). CONCLUSIONS: Oral mucositis was reduced in patients treated with RIC and in patients treated during recent years, when oral care was intensified. Increased scores of OM prolonged hospitalization.
PURPOSE:Oral mucositis (OM) is a side effect of intensive chemotherapy and radiation and has been reported to affect 75-100% of hematopoietic stem cell transplantation (HSCT) recipients. The purpose of this study was to compare the incidence of OM in patients conditioned with myeloablative conditioning (MAC) to reduced-intensity conditioning (RIC) and to determine the effect of a new oral care protocol. METHODS: The study involved 171 HSCT recipients, with hematological malignancies transplanted between 2007 and 2011. Median age of the patients was 50 years (range 12-71). Ninety-nine (58%) received RIC and 72 received MAC. Clinical features of OM were recorded from day -3 before to day +25 after HSCT using the World Health Organization (WHO) scoring system and the oral mucositis assessment score (OMAS). RESULTS: Overall, 87% of the patients developed OM of any severity, which peaked on days 10-11. The mean WHO score was 1.7. In multivariate analysis, the severity of OM was associated with MAC (relative hazard (RH) 1.57, 95% confidence interval (CI) 1.37-1.80, p < 0.001), all donor-recipient gender combinations except female-to-male (RH = 1.26, 95% CI 1.10-1.4, p = 0.001), and early year of HSCT (RH = 0.84, 95%CI 0.7-0.96, p = 0.013). There was a correlation between long hospitalization and OM (day 15, r = 0.31, p < 0.001). There was a good correlation between the WHO and OMAS scoring systems for OM (r = 0.74, p < 0.001). CONCLUSIONS:Oral mucositis was reduced in patients treated with RIC and in patients treated during recent years, when oral care was intensified. Increased scores of OM prolonged hospitalization.
Authors: S T Sonis; G Oster; H Fuchs; L Bellm; W Z Bradford; J Edelsberg; V Hayden; J Eilers; J B Epstein; F G LeVeque; C Miller; D E Peterson; M M Schubert; F K Spijkervet; M Horowitz Journal: J Clin Oncol Date: 2001-04-15 Impact factor: 44.544
Authors: A P Rapoport; L F Miller Watelet; T Linder; S Eberly; R F Raubertas; J Lipp; R Duerst; C N Abboud; L Constine; J Andrews; M A Etter; L Spear; E Powley; C H Packman; J M Rowe; U Schwertschlag; C Bedrosian; J L Liesveld Journal: J Clin Oncol Date: 1999-08 Impact factor: 44.544
Authors: Dorothy M Keefe; Mark M Schubert; Linda S Elting; Stephen T Sonis; Joel B Epstein; Judith E Raber-Durlacher; Cesar A Migliorati; Deborah B McGuire; Ronald D Hutchins; Douglas E Peterson Journal: Cancer Date: 2007-03-01 Impact factor: 6.860
Authors: Betânia Ferreira; Fabiana Moura da Motta Silveira; Flávia Augusta de Orange Journal: Support Care Cancer Date: 2015-08-07 Impact factor: 3.603
Authors: Mats Remberger; Johan Törlen; Ibrahim El Serafi; Karin Garming-Legert; Andreas Björklund; Per Ljungman; Mikael Sundin; Moustapha Hassan; Jonas Mattsson Journal: Int J Hematol Date: 2017-08-28 Impact factor: 2.490
Authors: Camila Weissheimer; Marina Curra; Lauro J Gregianin; Liane E Daudt; Vivian P Wagner; Marco Antonio T Martins; Manoela D Martins Journal: Lasers Med Sci Date: 2017-08-24 Impact factor: 3.161
Authors: Catherine H L Hong; Luiz Alcino Gueiros; Janet S Fulton; Karis Kin Fong Cheng; Abhishek Kandwal; Dimitra Galiti; Jane M Fall-Dickson; Jorgen Johansen; Suzanne Ameringer; Tomoko Kataoka; Dianna Weikel; June Eilers; Vinasha Ranna; Anusha Vaddi; Rajesh V Lalla; Paolo Bossi; Sharon Elad Journal: Support Care Cancer Date: 2019-07-08 Impact factor: 3.603
Authors: Karin Garming Legert; Georgios Tsilingaridis; Mats Remberger; Olle Ringdèn; Anders Heimdahl; Tülay Yucel-Lindberg; Göran Dahllöf Journal: Support Care Cancer Date: 2014-11-30 Impact factor: 3.603
Authors: Tove Kamsvåg; Anncarin Svanberg; Karin Garming Legert; Johan Arvidson; Louise von Essen; Karin Mellgren; Jacek Toporski; Jacek Winiarski; Gustaf Ljungman Journal: Support Care Cancer Date: 2020-01-28 Impact factor: 3.603